Skip to main content
Adlai Nortye Ltd. logo

Adlai Nortye Ltd. — Investor Relations & Filings

Ticker · ANL ISIN · US00704R1095 LEI · 54930009TDXE4YQVKU60 US Manufacturing
Filings indexed 69 across all filing types
Latest filing 2026-04-16 Foreign Filer Report
Country KY Cayman Islands
Listing US ANL

About Adlai Nortye Ltd.

https://www.adlainortye.com/

Adlai Nortye Ltd. is a global clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies. The company's pipeline is centered on two key areas: next-generation cancer immunotherapies and RAS-targeting therapies. Its immunotherapy candidates include AN8025, a tri-functional fusion protein designed as a T-cell and antigen-presenting cell modulator, and AN4005, an oral small-molecule PD-L1 inhibitor. For RAS-driven cancers, the company is advancing AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) that delivers a potent pan-RAS(ON) inhibitor.

Recent filings

Filing Released Lang Actions
6-K - Adlai Nortye Ltd. (0001944552) (Filer)
Foreign Filer Report
2026-04-16 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-11 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-09 English
6-K Filing
Foreign Filer Report
2026-02-03 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-20 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.